Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 661

Results For "ED"

9539 News Found

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands


Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba
News | January 18, 2023

Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba

This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba


AI to drive digital mammography equipment market in South Korea during 2015-2030: GlobalData
Medical Device | January 18, 2023

AI to drive digital mammography equipment market in South Korea during 2015-2030: GlobalData

AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”


Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering
News | January 18, 2023

Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering

Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates


Cipla launches Cippoint
News | January 18, 2023

Cipla launches Cippoint

Point-of-Care solution to facilitate clinicians in quick and effective decision making


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram
Policy | January 17, 2023

1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram

India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health


Lonza completes expansion to Solid Form Services Facility at Bend (US) site
News | January 17, 2023

Lonza completes expansion to Solid Form Services Facility at Bend (US) site

New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement


Vikas Lifecare’s in-house R&D Unit gets DSIR recognition
News | January 17, 2023

Vikas Lifecare’s in-house R&D Unit gets DSIR recognition

This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies